Literature DB >> 33390952

Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.

Ching-Yuan Wu1,2, Yu-Shih Lin3, Yao-Hsu Yang1,2,4, Li-Hsin Shu1, Yu-Ching Cheng1, Hung Te Liu1.   

Abstract

Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and the index compounds of GB-1 on the ACE2 and TMPRSS2 expression through in vitro and in vivo study. In our result, GB-1 can inhibit ACE2 and TMPRSS2 protein expression in HepG2 cells, 293T cells, and Caco-2 cells without cytotoxicity. For the mouse model, GB-1 treatment could decrease ACE2 and TMPRSS2 expression levels of the lung and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity. In the compositions of GB-1, 0.5-1 mg/ml of Glycyrrhiza uralensis Fisch. ex DC. extract could not inhibit ACE2 mRNA and protein expression in HepG2 cells. In addition, theaflavin-3-gallate could inhibit protein expression of ACE2 and TMPRSS2 without significant cytotoxicity. Our results suggest that GB-1 and theaflavin-3-gallate could act as potential candidates for prophylaxis or treatment of SARS-CoV-2 infection through inhibiting protein expression of ACE2 and TMPRSS2 for the further study.
Copyright © 2020 Wu, Lin, Yang, Shu, Cheng and Liu.

Entities:  

Keywords:  (+)-catechin 4; ACE2; SARS-CoV-2; TMPRSS; theaflavin; theaflavin 3-gallate

Year:  2020        PMID: 33390952      PMCID: PMC7773841          DOI: 10.3389/fphar.2020.584158

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  6 in total

1.  Epipharyngeal Abrasive Therapy Down-regulates the Expression of SARS-CoV-2 Entry Factors ACE2 and TMPRSS2.

Authors:  Kensuke Nishi; Shohei Yoshimoto; Soichiro Nishi; Toshiyuki Tsunoda; Jun Ohno; Michinobu Yoshimura; Kenji Hiromatsu; Takafumi Yamano
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 2.  Experimental Models of COVID-19.

Authors:  Luis A Caldera-Crespo; Michael J Paidas; Sabita Roy; Carl I Schulman; Norma Sue Kenyon; Sylvia Daunert; Arumugam R Jayakumar
Journal:  Front Cell Infect Microbiol       Date:  2022-01-05       Impact factor: 5.293

3.  Editorial: Ethnopharmacological Responses to the Coronavirus Disease 2019 Pandemic.

Authors:  Jia-Bo Wang; Adolfo Andrade-Cetto; Javier Echeverria; Jon Wardle; Hung-Rong Yen; Michael Heinrich
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

4.  Metabolomic and Pharmacologic Insights of Aerial and Underground Parts of Glycyrrhiza uralensis Fisch. ex DC. for Maximum Utilization of Medicinal Resources.

Authors:  Liang Jiang; Waheed Akram; Biaobiao Luo; Sheng Hu; Mohammad Omar Faruque; Shakeel Ahmad; Nasim Ahmad Yasin; Waheed Ullah Khan; Aqeel Ahmad; Alexander N Shikov; Jian Chen; Xuebo Hu
Journal:  Front Pharmacol       Date:  2021-06-01       Impact factor: 5.810

5.  Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M B Victor; Aleksandra Drelich; Siva S Panda; Andrea Altieri; Alexander V Kurkin; Chien-Te K Tseng; Christopher D Hillyer; Asim K Debnath
Journal:  Viruses       Date:  2021-12-31       Impact factor: 5.048

6.  Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.

Authors:  Ming-Shao Tsai; Wei-Tai Shih; Yao-Hsu Yang; Yu-Shih Lin; Geng-He Chang; Cheng-Ming Hsu; Reming-Albert Yeh; Li-Hsin Shu; Yu-Ching Cheng; Hung-Te Liu; Yu-Huei Wu; Yu-Heng Wu; Rou-Chen Shen; Ching-Yuan Wu
Journal:  Biomed Pharmacother       Date:  2022-03-09       Impact factor: 7.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.